1.0Bower Lab/ophth/bowerlabDavid Kinton/ophth/bowerlab/author/kinton/Home - Bower Labrich600338<blockquote class="wp-embedded-content" data-secret="dS7vBijY1J"><a href="/ophth/bowerlab/">Home</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="/ophth/bowerlab/embed/#?secret=dS7vBijY1J" width="600" height="338" title="“Home” — Bower Lab" data-secret="dS7vBijY1J" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
The Bower Lab Carolina Eye Research Institute Department of Ophthalmology The Bower lab’s research interests are focused on the identification of potential therapeutic strategies for the most common type of primary malignant intraocular tumors, uveal melanoma (UVM). UVM is particularly suited for a genetic-based therapeutic approach in that 80-90% of tumors exhibit a unique stepwise … Read more/ophth/bowerlab/wp-content/uploads/sites/1304/2022/08/ºÚÁÏÍø-SOM-Ophth-Logo-300x45.png